Protocols: Hillary Clinton takes aim at drug profiteers; Arena spins out a GPCR biotech incubator
An ailing Arena Pharmaceuticals is spinning out a new incubator company called Beacon Discovery that will work on developing a pipeline of G-Protein Coupled Receptors (GPCRs). Beacon will hunt up pharma partners for the work and Arena will collaborate on the work and hopefully earn a revenue stream from the startup. CEO Amit Munshi, who jumped from a crumbling biotech focused on biosimilars to Arena earlier in the year, says it’s all part of the plan to transform the company into a “high-performing clinical development organization.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
